News

  • 24 April 2017

    Sienna Biopharmaceuticals, Inc., a privately held, clinical stage medical dermatology and aesthetics company, today announced that it completed a $40 million Series B financing led by existing investors ARCH Venture Partners and Venvest Capital. Additional investors participating included Partner Fund Management, Altitude Life Science Ventures, and Dr. David Pyott.  New investors accounted for approximately half of the investments and included Fidelity Management & Research Company, certain investment funds advised by Clough Capital Partners L.P, Omega Fund Management, and others.  Sienna’s mission is to develop safe and effective targeted therapies to treat inflammatory skin conditions and aesthetic problems that impact the health, appearance, and quality of life of patients.

  • 18 April 2017

    Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and fecal dysfunction, announced today that initial results from its prospective, multicenter clinical study will be presented for the first time at the International Neuromodulation Society (INS) World Congress on May 30, 2017 in Edinburgh, Scotland.

  • 22 March 2017

    InDex Pharmaceuticals Holding AB (publ) today announced that the company hosted a well attended investigators’ meeting for the CONDUCT study on March 20-21, 2017 in Stockholm. CONDUCT is a phase IIb dose optimisation study with the drug candidate cobitolimod for the treatment of moderate to severe active ulcerative colitis.

  • 14 March 2017

    InDex Pharmaceuticals Holding AB (publ) today announced that a patent covering 19 compounds from the company’s DIMS platform has been granted by the United States Patent and Trademark Office (USPTO).

  • 8 March 2017

    InDex Pharmaceuticals Holding AB (publ) today announced that the company has appointed Johan Giléus as new Chief Financial Officer (CFO) from May 1, 2017.